Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 11Neoplasms 5Parasomnias 4Depression 3Weight Loss 2Tuberous Sclerosis 2Smith-Magenis Syndrome 2Sleep Wake Disorders 2Polycystic Ovary Syndrome 2Pain 2Lung Neoplasms 2Fatigue 2Cachexia 2Autism Spectrum Disorder 2Anxiety Disorders 2Angelman Syndrome 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sleep Disorders, Circadian Rhythm 1Relapsed Malignant Solid Tumor 1Radiodermatitis 1Radiation Injuries 1Quality of Life 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Melanoma 1Leukoplakia, Oral 1Keratosis, Actinic 1Hematologic Neoplasms 1Head and Neck Neoplasms 1

Interventions

Melatonin 2Sertraline 1Selective Serotonin Reuptake Inhibitors 1Registries 1Lovastatin 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Autism Spectrum Disorder × Melatonin × Clear all
NCT01906866 2024-04-23

Efficacy and Safety of CircadinĀ® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Neurim Pharmaceuticals Ltd.

Phase 3 Completed
125 enrolled 22 charts

Autism Spectrum Disorder, Sleep Wake Disorders, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

NCT01903681 2014-04-04

Assessment of the Pharmacokinetics of CircadinĀ® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Neurim Pharmaceuticals Ltd.

Phase 1 Completed
16 enrolled

Autism Spectrum Disorder, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔